Collegium Pharmaceutical (NASDAQ:COLL) Downgraded to "Buy" Rating by StockNews.com

StockNews.com cut shares of Collegium Pharmaceutical (NASDAQ:COLL - Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday morning.

Several other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reaffirmed a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, Piper Sandler lowered their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Up 1.4 %

Shares of COLL stock traded up $0.38 during mid-day trading on Friday, reaching $27.27. 8,234 shares of the company's stock traded hands, compared to its average volume of 443,165. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $42.29. The company has a market cap of $876.24 million, a P/E ratio of 11.75 and a beta of 0.76. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company's 50-day moving average price is $28.59 and its 200-day moving average price is $30.99.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. On average, equities analysts expect that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the sale, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. The trade was a 1.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 10,445 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the sale, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 81,693 shares of company stock valued at $2,334,994. Company insiders own 2.51% of the company's stock.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in the business. Janney Montgomery Scott LLC purchased a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at about $439,000. SummerHaven Investment Management LLC raised its position in shares of Collegium Pharmaceutical by 1.9% during the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock valued at $727,000 after buying an additional 448 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Collegium Pharmaceutical by 4.2% during the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company's stock valued at $426,000 after buying an additional 578 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Collegium Pharmaceutical by 4.5% during the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after buying an additional 477 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Collegium Pharmaceutical by 3.1% during the 1st quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company's stock valued at $3,332,000 after buying an additional 3,400 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.